Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has been given an average recommendation of "Buy" by the ten research firms that are currently covering the company, MarketBeat reports. Ten analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $27.89.
Several brokerages have issued reports on CNTA. Needham & Company LLC began coverage on shares of Centessa Pharmaceuticals in a report on Wednesday. They issued a "buy" rating and a $35.00 price target on the stock. Guggenheim reissued a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Chardan Capital began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued a "buy" rating and a $30.00 target price on the stock. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price on the stock. Finally, Piper Sandler began coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 target price on the stock.
Get Our Latest Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Stock Performance
Centessa Pharmaceuticals stock traded up $0.07 on Tuesday, hitting $13.14. The company's stock had a trading volume of 751,590 shares, compared to its average volume of 660,764. The firm has a market cap of $1.75 billion, a P/E ratio of -8.59 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average price of $12.73 and a 200-day moving average price of $15.34. Centessa Pharmaceuticals has a one year low of $7.90 and a one year high of $19.09.
Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.15. On average, equities analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.
Insider Buying and Selling
In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $16.45, for a total transaction of $98,700.00. Following the transaction, the general counsel now owns 105,386 shares in the company, valued at $1,733,599.70. This represents a 5.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David M. Chao sold 7,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the transaction, the insider now owns 225,007 shares in the company, valued at approximately $3,863,370.19. The trade was a 3.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 175,398 shares of company stock worth $2,551,442 in the last 90 days. Corporate insiders own 7.09% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in CNTA. GF Fund Management CO. LTD. bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $31,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock valued at $46,000 after acquiring an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at about $47,000. Barclays PLC increased its stake in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after acquiring an additional 4,952 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at about $147,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.
Centessa Pharmaceuticals Company Profile
(
Get Free ReportCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
See Also
Before you consider Centessa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Centessa Pharmaceuticals wasn't on the list.
While Centessa Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
